In this week’s episode, we are discussing two recent FDA approvals—one for prostate cancer, and the other for endometrial cancer. The radioconjugate lutetium Lu-177 vipivotide tetraxetan was approved for the treatment of adult patients with prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer who have been treated with androgen receptor pathway inhibition and taxane-based chemotherapy. Pembrolizumab was approved as a single agent for patients with advanced endometrial carcinoma that is microsatellite instability–high or mismatch repair–deficient as determined by an FDA-approved test; eligible patients have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.

Coverage of stories discussed this week on ascopost.com:

FDA Approves Radioligand for Metastatic Castration-Resistant Prostate Cancer

FDA Approves Pembrolizumab for Advanced Endometrial Carcinoma

To listen to more podcasts from ASCO, visit asco.org/podcasts.